PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E of 0.00 while GNPX has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
14.29
Dangerously higher net debt above 1.5x GNPX's 6.51. Jim Chanos would check for potential debt spiral risks.
-147.54
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
12.94
Current ratio 75-90% of GNPX's 14.97. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.